Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June...
BNY Reports Second Quarter 2026 Results
NEW YORK, July 15, 2026 /PRNewswire/ -- The Bank of New York Mellon Corporation ("BNY") (NYSE: BNY), a global financial services company, has reported financial results for the second quarter 2026. The company's earnings release along with the...
Initiative on Joint Promotion of World Cultural Heritage Launched in Chongzuo, China
CHONGZUO, China, July 15, 2026 /PRNewswire/ -- This is a report from china-asean-media.com. The 2026 ASEAN-China Cultural Exchange Cooperation Forum was held today in Chongzuo, Guangxi Zhuang Autonomous Region, co-hosted by the Bureau of...
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology...
MAKER'S MARK LAUNCHES AIRPORT-EXCLUSIVE ARTIST SERIES
In time for summer travel, artist Alexandra Pacula brings iconic cityscapes to life in a limited-edition series exclusively for global travel retail LORETTO, Ky., July 15, 2026 /PRNewswire/ -- Maker's Mark, the iconic handmade Kentucky bourbon,...
IBM Launches New Power Systems and Software Built for Enterprises to Address Risk, Productivity, and Flexibility
New IBM Power Autonomous Operations software identifies and resolves capacity constraints up to 15x1 faster than manually performing the operation IBM Bob™ Premium Package for i helps accelerate application development on IBM i Entry-level Power...
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC 50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC 50 = 3 pM) and is a selective agonist for GIPR...
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of...